<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409211</url>
  </required_header>
  <id_info>
    <org_study_id>17-00748</org_study_id>
    <nct_id>NCT03409211</nct_id>
  </id_info>
  <brief_title>Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis</brief_title>
  <acronym>PAMPPA</acronym>
  <official_title>Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof-of-principle, placebo-controlled, open label study to assess the improvement&#xD;
      in the Treg counts and PASI Scores with PEVCO given at 1000 mg four times daily in patients&#xD;
      with PsO (subjects may or may not have PsA) , who have active disease and are not currently&#xD;
      receiving other therapy (as defined by the inclusion/exclusion criteria) compared to healthy&#xD;
      subjects.&#xD;
&#xD;
      The patients and healthy controls will receive placebo or PEVCO for a total of 9 weeks (3&#xD;
      weeks for placebo, followed by 6 weeks for PEVCO). No topical or systemic medications will be&#xD;
      used during this period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in % of Treg Cells in Blood</measure>
    <time_frame>6 Weeks</time_frame>
    <description>% change in the expansion of regulatory T cells; demonstrate an increase in %Treg at 6 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in Medium Chain Fatty Acids (MCFA) content in the stool</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change in the amount of MCFA in stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in skin disease severity PASI scores 50</measure>
    <time_frame>12 Weeks</time_frame>
    <description>indicating 50% reduction in psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in skin disease severity PASI scores 75</measure>
    <time_frame>12 Weeks</time_frame>
    <description>indicating 75% reduction in psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in skin disease severity PASI scores 90</measure>
    <time_frame>12 Weeks</time_frame>
    <description>indicating 90% reduction in psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the tender joint/swollen joint (TJ/SJ) counts at 6 weeks.</measure>
    <time_frame>6 Weeks</time_frame>
    <description>To assess whether PEVCO 1000 mg four times daily for 6 weeks improves:&#xD;
66/68 Tender-joint count&#xD;
66/68 Swollen-joint count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Psoriasis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Pso</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with or without PsA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Without PsA</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PEVCO</intervention_name>
    <description>All subjects will receive PEVCO for 6 more weeks.</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>Pso</arm_group_label>
    <other_name>Coconut Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Supplement Capsules without Coconut Oil</intervention_name>
    <description>All subjects will receive placebo (PBO) for 3 weeks</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>Pso</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have an active [psoriatric plaque &gt;2cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of sensitivity to study compound or any of their excipients&#xD;
&#xD;
          -  Previous intolerance to PEVCO or related compounds&#xD;
&#xD;
          -  Current (within 3 months of screening) treatment with DMARDs&#xD;
&#xD;
          -  Current (within 3 months of screening) treatment with biologic therapies (including&#xD;
             but limited to anti-TNF,anti-IL-17, anti-IL-12/23)&#xD;
&#xD;
          -  Current antibiotic treatment (within 3 months of screening)&#xD;
&#xD;
          -  current consumption of probiotics (within 3 months of screening)&#xD;
&#xD;
          -  Severe hepatic impairment (eg, ac-sites and/or clinical signs of coagulopathy)&#xD;
&#xD;
          -  Renal failure (eGFR ,30 or require dialysis) by history&#xD;
&#xD;
          -  History of other autoimmune or inflammatory skin disease&#xD;
&#xD;
          -  Current immunodeficiency state (cancer, HIV, others)&#xD;
&#xD;
          -  Current immunodeficiency state (cancer, HIV, Other)&#xD;
&#xD;
          -  Concern for inability of the patient to comply with study procedure, and or follow up&#xD;
             (alcohol or drug abuse)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Scher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

